The Biodesign Institute at Arizona State University and Pohang University of Science and Technology (POSTECH) in Pohang, South Korea, have announced a partnership that will catalyze discoveries with a major impact on health care and clean energy applications.
Author Archive: AZBio
AMAG Pharmaceuticals Completes Acquisition of Cord Blood Registry
AMAG Pharmaceuticals Completes Acquisition of Cord Blood Registry
- Expands company’s growing maternal health business
- Transaction expected to be immediately accretive
- Company anticipates seamless integration and is well positioned for future acquisitions
Research study tests pancreatic cancer drug at Banner MD Anderson Cancer Center
Banner MD Anderson Cancer Center is testing the safety and effectiveness of a drug that, when combined with chemotherapy, may make a difference in treating pancreatic cancer in patients who carry harmful mutations of either the BRCA1 or BRCA2 genes.Continue reading
TGen study finds genes associated with improved survival for pancreatic cancer patients
Use of non-invasive liquid biopsies could predict in which patients the cancer could recur following surgeryContinue reading
EPVSensors Takes a Closer Look at Glaucoma
UA-developed technology may lead to a breakthrough in glaucoma detection and treatment.Continue reading
AZBio honors Lynn Hudson, Ph.D., Chief Science Officer of the Critical Path Institute, as the 2015 Arizona Bioscience Leader
Citing her leadership in advancing extremely complex biomedical research, the Arizona Bioindustry Association today announced that Lynn Hudson, Ph.D., Chief Science Officer for the Critical Path Institute, will be honored with the Jon W. McGarity Arizona Bioscience Leader of the Year Award, during ceremonies later this year.Continue reading
The Start of SynCardia Total Artificial Heart Destination Clinical Study Wins Edison Awards’ Top Honor
Gold Award recognizes the FDA approval of a study into the effectiveness of the SynCardia Total Artificial Heart powered by the Freedom® portable driver for end-stage biventricular heart failure patients who don’t qualify for donor heart transplants.Continue reading
SynCardia Systems, Inc. files Form S-1 for IPO
“SynCardia Systems, a developer and manufacturer of temporary implantable artificial hearts, filed on Monday with the SEC to raise up to $40 million in an initial public offering.” (Source) Continue reading
Opportunity Alert- Apply to NCATS for SBIR STTR Funding
The National Center for Advancing Translational Sciences (NCATS) has several open funding opportunities available for small businesses interested in commercializing translational technologies.Continue reading
Blackstone Ventures to acquire Lattice Biologics
Blackstone Ventures Inc. (TSX VENTURE:BLV) has entered into a letter of intent, subject to receipt of all applicable regulatory and shareholder approvals, to acquire Lattice Biologics Inc.Continue reading